The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster ...

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug ...

Drugmaker Merck & Co on Tuesday announced job and cost cuts it said will save $3 billion a year as it posted lower ...

Verona Pharma plc (NASDAQ:VRNA) is one of the best multibagger stocks according to hedge funds. On July 9, 2025, Merck & Co.

Merck & Co., Inc. (NYSE:MRK) is one of the top low volatility healthcare stocks to buy now. Analyst Daina Graybosch of ...

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...

Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Tuesday before market open. Here’s what ...

For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its ...

Merck is undervalued with strong growth, profitability, and credit strength despite CDMO challenges, offering compelling ...

Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of double-digit growth for its blockbuster cancer drug Keytruda, the world's top selling prescription medicine.

Merck has been named a Fortune 500 company in 2022 with awards for innovation, including CPhI Awards, R&D Magazine 100 awards, and the 2019 Innovation SABRE Award.

Merck & Co. shows their new antiviral medication. Pharmaceutical company Merck & Co. announced Friday, that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people ...